Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Standard therapy: • The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients (1200-1500 and 1000-1200 kcal/day for men and women, respectively).

Cilostazol: Cilostazol is a 2-hydroxyquinolone derivative and a drug approved for improving the claudication distance. Other studies have shown that Cilostazol can ameliorate hepatic steatosis, but the specific mechanism is still unknown

Study summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women

Eligibility

Primary outcome measure(s)

• The change in the degree of steatosis in the ultra sound and the change in fibrosis risk scores are the primary endpoint. — 3 months
  The change in the degree of steatosis in the ultra sound and the change in fibrosis risk scores are the primary endpoint.

Trial sites (1)

More Tanta University trials in Egypt

Other trials for the same condition